Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$23.26
+2.2%
$22.55
$18.70
$29.55
$1.08B1.79420,684 shs503,412 shs
Cutera, Inc. stock logo
CUTR
Cutera
$0.04
-63.9%
$0.04
$0.09
$1.87
$787K1.362.80 million shs27.70 million shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$128.73
+0.8%
$122.32
$55.00
$177.37
$4.37B2.061.37 million shs369,545 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.00%+8.24%+8.19%+11.40%+16.13%
Cutera, Inc. stock logo
CUTR
Cutera
0.00%0.00%0.00%0.00%-96.98%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
0.00%-2.07%-5.06%+90.22%-13.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.1253 of 5 stars
3.53.00.00.02.62.50.6
Cutera, Inc. stock logo
CUTR
Cutera
N/AN/AN/AN/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.6322 of 5 stars
1.42.00.00.02.42.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.00
Buy$31.1733.99% Upside
Cutera, Inc. stock logo
CUTR
Cutera
2.50
Moderate Buy$3.007,592.31% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.80
Moderate Buy$127.33-1.08% Downside

Current Analyst Ratings Breakdown

Latest CUTR, TMDX, and BLFS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$130.00 ➝ $150.00
6/17/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
6/4/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.00
6/3/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/13/2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/9/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.00
5/9/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.00
4/29/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$90.00 ➝ $105.00
4/23/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$82.25M13.43$0.12 per share186.43$7.52 per share3.09
Cutera, Inc. stock logo
CUTR
Cutera
$155.21M0.01N/AN/A($8.62) per share0.00
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$441.54M9.86$1.64 per share78.52$6.81 per share18.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$20.18M-$0.29N/AN/AN/A-11.81%-0.66%-0.58%8/14/2025 (Estimated)
Cutera, Inc. stock logo
CUTR
Cutera
-$162.83M-$6.58N/AN/AN/A-84.86%N/A-45.07%8/6/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$35.46M$1.3694.6590.02N/A10.03%21.88%6.15%7/30/2025 (Estimated)

Latest CUTR, TMDX, and BLFS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.48N/AN/AN/A$146.64 millionN/A
5/8/2025Q1 2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.03$0.04+$0.07-$0.01$22.22 million$23.94 million
5/8/2025Q1 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.29$0.70+$0.41$0.70$123.39 million$143.54 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
Cutera, Inc. stock logo
CUTR
Cutera
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.01
4.73
3.74
Cutera, Inc. stock logo
CUTR
Cutera
N/A
2.88
1.86
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.92
9.10
8.32

Institutional Ownership

CompanyInstitutional Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
Cutera, Inc. stock logo
CUTR
Cutera
90.70%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.20%
Cutera, Inc. stock logo
CUTR
Cutera
0.42%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
44047.50 million46.46 millionOptionable
Cutera, Inc. stock logo
CUTR
Cutera
46020.19 million20.10 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21033.82 million31.46 millionOptionable

Recent News About These Companies

TMDX - TransMedics Group Inc Executives - Morningstar
Analyzing TransMedics Group (NASDAQ:TMDX) and Teleflex (NYSE:TFX)
TransMedics Group, Inc. (TMDX) Cash Flow - Yahoo Finance
TMDX - TransMedics Group Inc Key Metrics - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioLife Solutions stock logo

BioLife Solutions NASDAQ:BLFS

$23.26 +0.51 (+2.24%)
Closing price 07/3/2025 03:36 PM Eastern
Extended Trading
$23.68 +0.41 (+1.78%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Cutera stock logo

Cutera NASDAQ:CUTR

$0.04 -0.07 (-63.86%)
Closing price 03/12/2025
Extended Trading
$0.04 0.00 (0.00%)
As of 03/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$128.72 +1.04 (+0.81%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$127.15 -1.57 (-1.22%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.